Stockscreener 앱 받기
1.505
0.00%
0.005
전일 마감가:
$1.50
열려 있는:
$1.52
하루 거래량:
170.96K
Relative Volume:
0.06
시가총액:
$405.06M
수익:
$236.20M
순이익/손실:
$-5.35M
주가수익비율:
-84.08
EPS:
-0.0179
순현금흐름:
$67.70M
1주 성능:
+5.63%
1개월 성능:
+8.70%
6개월 성능:
-29.25%
1년 성능:
-35.90%
1일 변동 폭
$1.50
$1.54
1주일 범위
$1.35
$1.54
52주 변동 폭
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.51 | 402.38M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
111.94 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.47 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.095 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
579.40 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Announces Vadadustat Post-hoc Win - GlobeNewswire
MSN Money - MSN
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Moomoo
Akebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Earnings Preview: AKBA to Report Financial Results Pre-market on May 07 - Moomoo
Are options traders betting on a big move in Akebia Therapeutics stock? - MSN
Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan
Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Akebia (AKBA) Road Ahead | Q4 2025: EPS Misses ViewsCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
Akebia (AKBA) Stock: Long-Term Outlook Review (Steady Climb) 2026-04-20Verified Analyst Reports - Cổng thông tin điện tử tỉnh Tây Ninh
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 - GuruFocus
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Potential Upside of 225.93% Draws Investor Attention - DirectorsTalk Interviews
AKBA Forecast, Price Target & Analyst Ratings | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill
AKBA Should I Buy - Intellectia AI
Akebia Therapeutics (NASDAQ: AKBA) asks shareholders to increase authorized stock - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com - Investing.com Australia
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Sahm
Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid - GuruFocus
Akebia doses first patients in Phase 1 trial of AKB-9090 - Investing.com Canada
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - The Manila Times
Akebia starts human testing of drug for kidney injury after heart surgery - Stock Titan
Profit Review: Is Akebia Therapeutics Inc attractive for institutional investorsGDP Growth & Momentum Based Trading Ideas - baoquankhu1.vn
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research - MarketBeat
Sectors Review: Is Akebia Therapeutics Inc stock trending bullishWeekly Risk Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Block Trades: What is the next catalyst for Akebia Therapeutics IncQuarterly Profit Review & Consistent Growth Stock Picks - baoquankhu1.vn
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - marketscreener.com
BTIG Reiterates Buy Rating on AKBA with $4.00 Price Target | AKB - GuruFocus
BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia executives head to New York for Apr. 14 biotech investor meetings - Stock Titan
H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA) - The Globe and Mail
Sell Signal: Does Akebia Therapeutics Inc offer margin of safetyMarket Trend Review & Smart Allocation Stock Tips - baoquankhu1.vn
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Fed Meeting: Is Akebia Therapeutics Incs ROIC above industry average2026 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) stock price, news, quote and history - Yahoo Finance UK
H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy By Investing.com - Investing.com Canada
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance
Aug Sectors: What is the next catalyst for Akebia Therapeutics Inc2026 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D DaySlideshow (NASDAQ:AKBA) 2026-04-04 - Seeking Alpha
Institutional Sell-Offs and Quiet Insiders Reveal Weak Confidence Behind Akebia's Pipeline Promotion - Bitget
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
2.00%
자본화:
|
볼륨(24시간):